Patents by Inventor Andrew Avery

Andrew Avery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR TREATING CANCER
    Publication number: 20260007748
    Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.
    Type: Application
    Filed: August 29, 2025
    Publication date: January 8, 2026
    Inventors: Kevin M. Friedman, Molly R. PerKins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • Compositions for treating cancer
    Patent number: 12440564
    Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.
    Type: Grant
    Filed: October 17, 2024
    Date of Patent: October 14, 2025
    Assignee: Kelonia Therapeutics, Inc.
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • Antigen binding polypeptides
    Patent number: 12435140
    Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.
    Type: Grant
    Filed: April 7, 2025
    Date of Patent: October 7, 2025
    Assignee: Kelonia Therapeutics, Inc.
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • Compositions for treating cancer
    Patent number: 12403194
    Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.
    Type: Grant
    Filed: October 17, 2024
    Date of Patent: September 2, 2025
    Assignee: Kelonia Therapeutics, Inc.
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20250257125
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: February 4, 2025
    Publication date: August 14, 2025
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • ANTIGEN BINDING POLYPEPTIDES
    Publication number: 20250236672
    Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.
    Type: Application
    Filed: April 7, 2025
    Publication date: July 24, 2025
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20250215072
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: September 17, 2024
    Publication date: July 3, 2025
    Inventors: Abhishek Datta, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. Dagbay, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • Antigen binding polypeptides
    Patent number: 12269882
    Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.
    Type: Grant
    Filed: October 17, 2024
    Date of Patent: April 8, 2025
    Assignee: Kelonia Therapeutics, Inc.
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • ANTIGEN BINDING POLYPEPTIDES
    Publication number: 20250101106
    Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.
    Type: Application
    Filed: October 17, 2024
    Publication date: March 27, 2025
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • COMPOSITIONS FOR TREATING CANCER
    Publication number: 20250099615
    Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.
    Type: Application
    Filed: October 17, 2024
    Publication date: March 27, 2025
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • COMPOSITIONS FOR TREATING CANCER
    Publication number: 20250099587
    Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.
    Type: Application
    Filed: October 17, 2024
    Publication date: March 27, 2025
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • ANTIGEN BINDING POLYPEPTIDES
    Publication number: 20250101122
    Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.
    Type: Application
    Filed: October 17, 2024
    Publication date: March 27, 2025
    Inventors: Kevin M. Friedman, Molly R. Perkins, Connor S. Dobson, Stephen L. Sazinsky, Shannon G. Contrastano, Emily Thompson Beura, Cory Ahonen, Andrew Avery
  • Methods of screening for high-affinity, isoform-selective TGF?1 inhibitors
    Patent number: 12252531
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: March 18, 2025
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • Isoform-selective TGFB1 inhibitors and use thereof
    Patent number: 12122823
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 22, 2024
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • Home and personal care compositions comprising silicon-based lubricants
    Publication number: 20060100126
    Abstract: A composition for personal, home, or laundry treatment comprising a polymer made up of one or more crosslinked rake or comb silicone copolymer segments. A process for making copolymers for use in such compositions involves hydrosilylation in the presence of a catalyst.
    Type: Application
    Filed: December 29, 2003
    Publication date: May 11, 2006
    Inventors: Andrew Avery, Dominique Charmot, Jean Frechet, Damian Hajduk, Ezat Khoshdel, Mingjun Liu